Sign Up for a Free Account

01.07.2022

Risk of overactive bladder associated with medications for dementia

A study from the University of Houston College of Pharmacy, and published in the Journal of the American Geriatrics Society, has evaluated the risk of overactive bladder as a side effect of cholinesterase inhibitor (ChEI) drugs taken for dementia and Alzheimer disease. The research was based on the dissertation work of the study’s first author Prajakta Masurkar.

Dementia is a group of symptoms associated with a decline in memory, reasoning or other thinking skills. Alzheimer disease is the most common cause of dementia, accounting for 60% to 80% of cases. ChEI drugs, including donepezil, galantamine and rivastigmine, increase communication between nerve cells to enhance cognition.

“The study found that the risk of overactive bladder varies across individual ChEIs,” reports Rajender R Aparasu, Mustafa, and Sanober Lokhandwala Endowed Professor of Pharmacy and chair, Department of Pharmaceutical Health Outcomes and Policy. “Using a national cohort of older adults with dementia, we also found that donepezil was associated with a 13% increased risk of overactive bladder compared to rivastigmine, whereas there was no differential risk of overactive bladder with galantamine and rivastigmine.”

Using Medicare data, the study examined 524,975 adults (aged 65 and older) with dementia who were users of ChEIs (donepezil 80.72%, rivastigmine 16.41%, galantamine 2.87%). The primary outcome of interest was overactive bladder diagnosis or prescription of antimuscarinics, drugs, which help correct overactive bladder, within six months of ChEI initiation.

While some studies have been conducted to evaluate the effects of all ChEIs and antimuscarinic use, few studies have been conducted regarding the effects of individual ChEIs on the risk of overactive bladder. Previous studies have found that the use of ChEIs is associated with an increased risk of receiving an antimuscarinic drug.

This study opens a new door.

“The findings suggest the need to understand and manage medication-related morbidity in older adults with dementia,” said Aparasu.

Source: News Release
University of Houston

January 6, 2022

Questions or Comment?

MedLink, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com